Key performanceindicators

Essential for Zealand’s success is our ability to constantly innovate and grow our product portfolio and pipeline of novel attractive medicines, and to ensure an increasing revenue stream and ensure financial solidity. 

Zealand key performance indicators for 2014 and onwards


Grow the value of our pipeline, advancing novel medicines
towards the market

  • Pipeline advances in terms of shifts to the next stage of development (two per year)
  • Speed of transition from preclinical to clinical development (One IND per two years)

Increase the proprietary (unpartnered) part of the pipeline

  • Number of pipeline assets where Zealand retains full or partial rights and thus substantial value upside

Grow the portfolio of partnerships

  • Number of big pharma partnerships (offering late stage clinical and commercial strength, financing and risk mitigation) 

Generate growing revenues and retain solid financial position

  • Royalty revenue growth (quarter/quarter, year/year)
  • Sum of total potential milestone payments from partners
  • Retain a cash position corresponding to at least 18 months of net operational expenses